Page 109 - Haematologica-April 2018

Metabolic syndrome in childhood leukemia survivors
from the IPC population to the general French population. In summary, our study suggests that metabolic syn- drome may develop through different mechanisms, depending on the treatments received. In the present study, we used age-matched controls, which enabled us to accurately evaluate metabolic syndrome risk in this young AL survivor population (mean age: 24 years), regardless of the fact that metabolic syndrome prevalence among indi- viduals in this young age range is poorly described. This prevalence will probably increase with age, as is the case
for the general population.23
In conclusion, this study reveals an increased risk of
metabolic syndrome among adult survivors of AL, regardless of the treatment they received. Moreover, metabolic syndrome seems to be more severe in the LEA patients than in the control group. The highest risk is observed in patients who received TBI, a group that dis- plays a specific metabolic profile, but all patients treated for childhood AL should be considered at risk of meta- bolic syndrome, regardless of the treatment they
received, even in the case of chemotherapy only. We hypothesize that if early detection of metabolic syn- drome is followed by changes in lifestyle (e.g. improved eating habits, more physical activity), it will help to pre- vent cardiovascular events in this at-risk population.36 We are currently planning controlled intervention studies in order to explore such an approach.
Funding
The study was funded by the French National Clinical Research Program, the French National Cancer Institute (InCA), the “Laurette Fugain” association, the French National Research Agency (ANR), the “Ligue Contre le Cancer” association, Cancéropôle PACA, the Regional Council PACA and the French Institute for Public Health Research (IRESP).
Acknowledgments
The authors would like to thank the LEA study group (Supplemental Data), for data collection, as well as the patients and their family.
References
1. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010;24(2):320-334.
2. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adoles- cents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30(14):1663-1669.
3. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541-1552.
4. Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2015;33(27):2949-2962.
5. Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposo- mal daunorubicin with idarubicin as induc- tion for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood. 2013;122(1):37-43.
6. Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the ran- domized phase III Children's Oncology Group trial AAML0531. J Clin Oncol. 2014;32(27):3021-3032.
7. Bhatia S, Armenian SH, Armstrong GT, et al. Collaborative Research in Childhood Cancer Survivorship: The Current Landscape. J Clin Oncol. 2015;33(27):3055- 3064.
8. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113-1132.
9. Ford ES. Risks for all-cause mortality, car- diovascular disease, and diabetes associat- ed with the metabolic syndrome: a summa- ry of the evidence. Diabetes Care. 2005;28(7):1769-1778.
10. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a system- atic review and meta-analysis of longitudi- nal studies. J Am Coll Cardiol. 2007;49(4):403-414.
11. Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syn- drome and cardiovascular risk among long- term survivors of acute lymphoblastic leukaemia - From the St. Jude Lifetime Cohort. Br J Haematol. 2014;165(3):364- 374.
12. Eschwege E. The dysmetabolic syndrome, insulin resistance and increased cardiovas- cular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the devel- opment of CV complications. Diabetes Metab. 2003;29(4 Pt 2):6S19-27.
13. Oudin C, Simeoni MC, Sirvent N, et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood. 2011;117(17):4442-4448.
14. Oudin C, Auquier P, Bertrand Y, et al. Metabolic syndrome in adults who received hematopoietic stem cell transplan- tation for acute childhood leukemia: an LEA study. Bone Marrow Transplant. 2015;50(11):1438-1444.
15. Saultier P, Auquier P, Bertrand Y, et al. Metabolic syndrome in long-term survivors of childhood acute leukemia treated with- out hematopoietic stem cell transplanta- tion: an L.E.A. study. Haematologica. 2016;101(12):1603-1610.
16. Majhail NS, Flowers ME, Ness KK, et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell trans- plantation. Bone Marrow Transplant. 2009;43(1):49-54.
17. Oeffinger KC, Adams-Huet B, Victor RG, et al. Insulin resistance and risk factors for car- diovascular disease in young adult sur- vivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2009;27(22):3698- 3704.
18. Friedman DN, Hilden P, Moskowitz CS, et al. Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body
Irradiation: A Longitudinal Analysis. Biol Blood Marrow Transplant. 2017;23(3):475- 482.
19. Ervin RB. Prevalence of metabolic syn- drome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003- 2006. Natl Health Stat Report. 2009;(13):1- 7.
20. Procopiou M, Philippe J. The metabolic syndrome and type 2 diabetes: epidemio- logical figures and country specificities. Cerebrovasc Dis. 2005;20(Suppl 1):2-8.
21. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in world- wide populations. Endocrinol Metab Clin North Am. 2004;33(2):351-375.
22. Oeffinger KC. Are survivors of acute lym- phoblastic leukemia (ALL) at increased risk of cardiovascular disease? Pediatr Blood Cancer. 2008;50(2 Suppl):462-467.
23. Pannier B, Thomas F, Eschwege E, et al. Cardiovascular risk markers associated with the metabolic syndrome in a large French population: the "SYMFONIE" study. Diabetes Metab. 2006;32(5 Pt 1):467-474.
24. Vernay M, Salanave B, de Peretti C, et al. Metabolic syndrome and socioeconomic status in France: The French Nutrition and Health Survey (ENNS, 2006-2007). Int J Public Health. 2013;58(6):855-864.
25. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640- 1645.
26. Scuteri A, Vuga M, Najjar SS, et al. Education eclipses ethnicity in predicting the development of the metabolic syn- drome in different ethnic groups in midlife: the Study of Women's Health Across the Nation (SWAN). Diabet Med. 2008;25(12):1390-1399.
27. Berbis J, Michel G, Baruchel A, et al.
haematologica | 2018; 103(4)
653